October 5, 2017
FDA issues Safety Alert for intraocular TMV injections
Editor's Note
The Food & Drug Administration (FDA) on October 3 issued a Safety Alert saying the agency had received an adverse event report on a patient who was diagnosed with bilateral hemorrhagic occlusive retinal vasculitis after being administered injections of a compounded triamcinolone, moxifloxacin, vancomycin (TMV) formulation in each eye at the end of cataract surgery procedures that were done 2 weeks apart.
The TMV formulation was compounded by Imprimis Pharmaceuticals (Ledgewood, New Jersey).
Free Daily News
- 5 reasons why perioperative leaders deserve to attend the 2025 OR Manager Conference
- Global medical community rejects Trump’s Tylenol-autism claims: Statements compilation
- Surgery, implantable devices offer new hope for drug-resistant epilepsy
- Remote monitoring speeds recovery, lowers complications after cancer surgery
- Common supplements may heighten bleeding risk during surgery, Polish study finds
- Keeping sensory aids in place during surgery reduces delirium risk in older hip fracture patients
- HFMA warns affordability crisis is driving up provider bad debt
- Report warns sterile processing staffing crisis threatens surgical safety
- Ascension swings to profit as outpatient push, cost cuts take hold
- High BMI alone did not raise early complication risk after outpatient TJA
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement